Insider Selling: uniQure (NASDAQ:QURE) Director Sells 1,993 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director Leonard Post sold 1,993 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $53,930.58. Following the completion of the sale, the director directly owned 35,494 shares of the company’s stock, valued at approximately $960,467.64. This trade represents a 5.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

uniQure Stock Performance

Shares of NASDAQ QURE traded up $0.75 during trading hours on Friday, reaching $27.57. The stock had a trading volume of 835,627 shares, compared to its average volume of 2,601,234. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The firm has a 50-day moving average of $22.31 and a 200-day moving average of $21.76.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The firm had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Equities research analysts predict that uniQure N.V. will post -3.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Stifel Nicolaus set a $28.00 target price on uniQure in a research note on Tuesday, May 5th. Chardan Capital boosted their target price on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $12.00 to $35.00 in a report on Wednesday, March 11th. Leerink Partners reissued an “outperform” rating and issued a $35.00 target price on shares of uniQure in a report on Monday, March 2nd. Finally, Barclays dropped their target price on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, March 23rd. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus price target of $42.83.

Hedge Funds Weigh In On uniQure

A number of large investors have recently modified their holdings of QURE. Woodline Partners LP raised its stake in shares of uniQure by 25.0% during the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after buying an additional 35,175 shares in the last quarter. Legal & General Group Plc purchased a new position in shares of uniQure during the 2nd quarter worth approximately $497,000. Marshall Wace LLP raised its stake in shares of uniQure by 276.5% during the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock worth $3,108,000 after buying an additional 163,749 shares in the last quarter. California State Teachers Retirement System purchased a new position in shares of uniQure during the 2nd quarter worth approximately $540,000. Finally, Ameriprise Financial Inc. raised its stake in shares of uniQure by 38.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after buying an additional 212,218 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.